Business Wire

AZ-EDGIO

22.2.2024 14:01:35 CET | Business Wire | Press release

Share
Web Application Attacks Intensify in Fourth Quarter of 2023, According to New Edgio Quarterly Attack Trends Report

Edgio (NASDAQ: EGIO), the platform of choice for speed, security, and simplicity at the edge, found that web application attacks continued to increase and evolve in the fourth quarter of 2023, as reported in its new Edgio Quarterly Attack Trends Report in which the company analyzed 5.2 billion attack requests. Edgio found that the most prevalent attack mitigated was path traversal. A successful path traversal attack allows a threat actor to access files on a web server, and has surpassed the prior #1 threat, SQL injection, a common attack vector that often uses malicious SQL statements to attempt to exfiltrate sensitive data from databases behind applications.

Edgio’s report explains how path traversal attacks can lead to deep system intrusions posing a significant threat to an organization’s infrastructure and the confidentiality, integrity, and availability of data delivered over the Internet. These attacks can result in unauthorized access to content, the loss of personally identifiable information (PII), the dissemination of private/copyrighted information, or even remote code execution. Unmitigated attacks can lead to even more serious consequences, such as the deployment of ransomware or other malicious software.

“As one of the leading edge-computing providers, Edgio has unparalleled visibility into the threats facing web applications today,” said Tom Gorup, Vice President of Security for Edgio. “We are assembling our knowledge and expertise into a quarterly read-out to enable enterprises to better protect their web infrastructure and applications. As more businesses become dependent on their digital assets, it’s critical this knowledge is shared to build a safer Internet.”

The report looked at malicious requests and the different types of blocking, categorizing protection into three categories: access control rules, managed rulesets, and custom signatures. Of those that were focused on access controls, over 76% of mitigated requests were based on IP, user-agent, and country matches, highlighting just how much bad traffic can be eliminated with basic blocklisting tactics. With managed rulesets, Edgio saw a wide range of threat types blocked, with path traversal, SQL injection and cross-site scripting (XSS) attacks leading the way when it comes to OWASP attacks.

In addition, Edgio was able to review web application firewall (WAF) request denials by country of origin, while noting that attackers often leverage local resources to launch attacks in order to evade geofencing tactics. This could explain why attacks coordinated from advanced threat actors in more prominent countries did not crack Edgio’s Top 10 for the quarter.

Top countries by malicious request origin, making up nearly 62% of all requests denied, include:

  • United States – 26.3%
  • France – 17.4%
  • Germany – 9.4%
  • Russia – 8.8%

Edgio found that WAF customers used access control features to allow or deny specific request methods, using their knowledge of their own applications to inform their security controls and lower risk. The report indicates that attackers frequently leverage request methods like HEAD that return app and infrastructure information that can be used by the attacker for reconnaissance purposes and to craft a malicious payload.

Based on deep parsing of attack payloads, Edgio found that 98% of all malicious payloads fell into JavaScript Object Notation (JSON) and URL encoded form categories (used for storing and transporting data) but cautioned security teams to remain vigilant as attackers evolve in their selection of payload content types.

Best practices for digital asset protection: proactively stop threats against websites and applications

Based on its findings, Edgio recommends the following methods to best protect digital assets, including websites and applications:

  • Ensure your WAF provides a layered defense to protect organizations against the known bad, application-specific, and emerging threats. A complete solution will show a distribution of enforcement across access control rules, managed rulesets, and custom signatures.
  • Blocklists are still an effective and low-cost part of a layered security approach to safeguard Internet-facing assets. Organizations should also take advantage of threat intelligence feeds to further harden their security posture against known bad actors.
  • While managed rules are often maintained and updated by your WAF provider, it is not advisable to use a ‘set it and forget’ approach. As an application evolves and new functionalities are developed, policy reviews and analysis of managed ruleset enforcement is recommended. It is best to ensure rules are closely aligned with business application needs.
  • Organizations should take the time to understand where they are doing business and where they aren’t allowed to do business. Block the countries or sub-regions that bring no value to a brand to reduce their attack surface. Blocking embargoed countries is a great starting point, but don’t rely on this approach as a catch all for bad actors.
  • Know the application and use this knowledge to inform security solutions, like a WAF, to limit the application request methods or content types based on application needs.

To obtain a full copy of the report, click here.

About Edgio

Edgio (NASDAQCM: EGIO) helps companies deliver online experiences and content faster, safer and with more control. Our developer-friendly, globally scaled edge network, combined with our fully integrated application and media solutions, provides a single platform for delivering high-performing, secure web properties and streaming content. Companies can deliver content quicker and more securely through this fully integrated platform and end-to-end edge services, boosting overall revenue and business value. To learn more, visit edg.io and follow us on Twitter, LinkedIn and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222674952/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye